CSIMarket
 


Accustem Sciences Inc   (ACUT)
Other Ticker:  
 

Accustem Sciences Inc 's Working Capital Ratio

ACUT's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




ACUT Working Capital Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter


Y / Y Current Liabilities Change - - - - -
Y / Y Current Assets Change - - - - -
Working Capital Ratio MRQ 1.96 3.24 5.78 - -
Overall Ranking # 2502 # 2502 # 0 # #
Seq. Current Liabilities Change 12.78 % 30.35 % - - -
Seq. Current Assets Change -31.97 % -26.88 % - - -



Working Capital Ratio third quarter 2022 Comment
Due to increase in Current Liabilities in the third quarter 2022, Working Capital Ratio fell to 1.96 below Accustem Sciences Inc average.

Within Major Pharmaceutical Preparations industry 423 other companies have achieved higher Working Capital Ratio than Accustem Sciences Inc in third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. 2502.

Explain Working Capital Ratio
Where is ACUT most successful ?
Working Capital Ratio ACUT on the trailing twelve month basis
Working Capital Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 424
Healthcare Sector # 820
Overall Market # 2502


Working Capital Ratio Statistics
High Average Low
5.78 3.66 1.96
(Mar 31 2022)   (Sep 30 2022)




Financial Statements
Accustem Sciences Inc 's Current Liabilities $ 1 Millions Visit ACUT's Balance sheet
Accustem Sciences Inc 's Current Assets $ 2 Millions Visit ACUT's Balance sheet
Source of ACUT's Sales Visit ACUT's Sales by Geography


Cumulative Accustem Sciences Inc 's Working Capital Ratio

ACUT's Working Capital Ratio for the trailling 12 Months

ACUT Working Capital Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter


Y / Y Current Liabilities TTM Growth - - - - -
Y / Y Current Assets TTM Growth - - - - -
Working Capital Ratio TTM 3.42 4.35 5.78 - -
Total Ranking TTM # # # # #
Seq. Current Liabilities TTM Growth 12.78 % 30.35 % - - -
Seq. Current Assets TTM Growth -31.97 % -26.88 % - - -


TTM Working Capital Ratio Comment
On the trailing twelve months basis Due to increase in Current Liabilities in the III. Quarter to $0.82 millions, average cumulative Working Capital Ratio decreased to 3.42 above the ACUT average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry ACUT achieved the highest Working Capital Ratio. While overall ranking remained unchanged compare to previous quarter at no. 0.

Explain Working Capital Ratio
Where is ACUT most successful ?
Working Capital Ratio ACUT on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Within the Market # 0


TTM Working Capital Ratio Statistics
High Average Low
0 0 0
 




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2022 MRQ Current AssetsSep 30 2022 MRQ Current Liabilities
Arvinas Inc   5.33 $ 1,304.700  Millions$ 244.600  Millions
Amylyx Pharmaceuticals Inc   5.27 $ 172.199  Millions$ 32.647  Millions
Biovie Inc   5.27 $ 21.590  Millions$ 4.096  Millions
Nurix Therapeutics Inc.  5.26 $ 354.871  Millions$ 67.500  Millions
Biomarin Pharmaceutical Inc  5.15 $ 2,682.701  Millions$ 521.020  Millions
Arbutus Biopharma Corp  5.13 $ 141.136  Millions$ 27.506  Millions
Sarepta Therapeutics Inc   5.11 $ 2,625.929  Millions$ 513.672  Millions
Adial Pharmaceuticals Inc   5.10 $ 6.773  Millions$ 1.327  Millions
Ampio Pharmaceuticals inc   5.10 $ 18.321  Millions$ 3.592  Millions
Procyon Corp  5.06 $ 2.418  Millions$ 0.478  Millions
Frequency Therapeutics Inc   5.05 $ 100.990  Millions$ 20.003  Millions
Tg Therapeutics inc   5.02 $ 182.922  Millions$ 36.447  Millions
Hookipa Pharma inc   4.98 $ 129.611  Millions$ 26.052  Millions
Ocular Therapeutix Inc   4.98 $ 145.615  Millions$ 29.269  Millions
Impel Pharmaceuticals Inc   4.97 $ 99.276  Millions$ 19.963  Millions
Verastem Inc   4.97 $ 108.759  Millions$ 21.873  Millions
Oncorus Inc   4.97 $ 83.479  Millions$ 16.813  Millions
Clever Leaves Holdings Inc   4.93 $ 40.546  Millions$ 8.218  Millions
Ultragenyx Pharmaceutical Inc   4.76 $ 1,012.668  Millions$ 212.584  Millions
Praxis Precision Medicines Inc   4.72 $ 132.312  Millions$ 28.006  Millions
Vertex Pharmaceuticals Inc  4.70 $ 12,271.000  Millions$ 2,609.300  Millions
Neurobo Pharmaceuticals Inc   4.67 $ 7.554  Millions$ 1.619  Millions
Aeglea Biotherapeutics Inc   4.65 $ 82.219  Millions$ 17.678  Millions
Nighthawk Biosciences inc   4.60 $ 66.474  Millions$ 14.451  Millions
Trevena inc   4.60 $ 42.540  Millions$ 9.257  Millions
Insmed Inc  4.59 $ 632.165  Millions$ 137.654  Millions
Acadia Pharmaceuticals Inc   4.48 $ 521.700  Millions$ 116.570  Millions
Revelation Biosciences Inc   4.45 $ 6.505  Millions$ 1.463  Millions
Durect Corp  4.44 $ 59.346  Millions$ 13.357  Millions
Vaccinex Inc   4.40 $ 8.025  Millions$ 1.824  Millions

Date modified: 2022-11-28T12:27:03+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

MF's Profile

Stock Price

MF's Financials

Business Description

Fundamentals

Charts & Quotes

MF's News

Suppliers

MF's Competitors

Customers & Markets

Economic Indicators

MF's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071